Hamps Bio board approves remuneration hike for directors and KMPs
- Board approved remuneration hikes for CMD Herrik Mountbaton Shah and WTD Shrenikkumar Mountkumar Shah
- CFO Mitali Shrenikkumar Shah also received an approved increase in pay
- Remuneration for Director Pallavi Herrik Shah was approved by the board
- Decisions were based on Nomination and Remuneration committee recommendations
- Meeting held on September 9, 2026, complied with SEBI Listing Regulations

*this image is generated using AI for illustrative purposes only.
Hamps Bio Limited board of directors approved remuneration increases for its Chairman and Managing Director, Whole Time Director, Chief Financial Officer, and a director during a meeting held on September 9, 2026. The decisions were made based on recommendations from the Nomination and Remuneration committee.
The corporate governance move affects key leadership roles within the Gujarat-based chemical manufacturer. The board meeting commenced at 5:00 pm and concluded at 5:45 pm at the company's corporate office.
Remuneration Approvals
The board considered and approved the following changes to executive compensation:
- Increase in remuneration for Mr. Herrik Mountbaton Shah, Chairman and Managing Director (DIN: 01052316)
- Increase in remuneration for Mr. Shrenikkumar Mountkumar Shah, Whole Time Director (DIN: 00973690)
- Increase in remuneration for Mrs. Mitali Shrenikkumar Shah, Chief Financial Officer
- Approval of remuneration for Mrs. Pallavi Herrik Shah, Director (DIN: 10418931)
All approvals followed recommendations received from the Nomination and Remuneration committee.
Regulatory Disclosure
The company issued this disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was signed by Ravi Baheti, Company Secretary & Compliance Officer.
Hamps Bio operates manufacturing units in Ankleshwar and Surat, Gujarat.
Historical Stock Returns for Hamps Bio
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | -1.54% | 0.0% | 0.0% | 0.0% | 0.0% |
How will the increased executive compensation impact Hamps Bio's net profit margins in the upcoming fiscal quarters?
Are there any pending performance-linked incentives or bonus structures tied to these remuneration increases for the key leadership roles?
What is the market's reaction to this governance decision, and has there been any notable movement in Hamps Bio's stock price following the disclosure?


































